Verastem, Inc. - Common Stock (NQ:VSTM)

7.750 -0.250 (-3.12%)

Delayed Quote Updated: 4:00 PM EDT, Oct 6, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Verastem, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

October 07, 2022

From Verastem Oncology

Via Business Wire

Why KalVista Pharmaceuticals Shares Are Trading Lower By 59%; Here Are 89 Biggest Movers From Yesterday ↗

October 05, 2022

Losers

Via Benzinga

S&P 500 Rises 100 Points; Nasdaq Up 3% ↗

October 04, 2022

U.S. stocks traded higher toward the end of trading, with the Nasdaq Composite climbing more than 300 points on Tuesday.

Via Benzinga

RBC Says Verastem Interim Analysis In Ovarian Cancer Reinforces Enthusiasm ↗

June 07, 2022

Via Benzinga

Recap: Verastem Q4 Earnings ↗

March 28, 2022

Verastem (NASDAQ:VSTM) reported its Q4 earnings results on Monday, March 28, 2022 at 07:00 AM. Here's what investors need to know about the announcement.

Via Benzinga

Stocks That Hit 52-Week Lows On Wednesday ↗

October 05, 2022

Wednesday saw 127 companies set new 52-week lows.

Via Benzinga

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

October 04, 2022

Gainers

Via Benzinga

Why AeroClean Technologies Shares Are Trading Higher By Around 38%, Here Are 58 Stocks Moving In Tuesday's Mid-Day Session ↗

October 04, 2022

Gainers Bit Brother Limited (NASDAQ: BTB) rose 229% to $0.3688 after declining around 14% on Monday.

Via Benzinga

Stocks That Hit 52-Week Lows On Tuesday ↗

October 04, 2022

On Tuesday, 44 companies hit new 52-week lows.

Via Benzinga

Nasdaq Surges 350 Points; Crude Oil Rises Sharply ↗

October 04, 2022

U.S. stocks traded higher midway through trading, with the Nasdaq Composite climbing more than 350 points on Tuesday.

Via Benzinga

Verastem Oncology Announces RAMP VS-6766 Clinical Trials and Corporate Updates

October 04, 2022

From Verastem Oncology

Via Business Wire

Verastem Oncology Reports Second Quarter 2022 Financial Results and Highlights Recent Company Progress

August 08, 2022

From Verastem Oncology

Via Business Wire

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

July 07, 2022

From Verastem Oncology

Via Business Wire

Verastem Oncology Provides Update on RAMP 201 Study Evaluating VS-6766 ± Defactinib in Low-Grade Serous Ovarian Cancer

June 06, 2022

From Verastem Oncology

Via Business Wire

7 Cheap Biotech Stocks to Buy Now ↗

May 19, 2022

These biotech stocks can be speculative, but have the potential to blow up in the next couple of years for good gains.

Via InvestorPlace

Verastem Oncology Awarded Pancreatic Cancer Action Network’s First Therapeutic Accelerator Award to Evaluate the Combination of VS-6766 and Defactinib in Front-Line Metastatic Pancreatic Cancer

May 18, 2022

From Verastem Oncology

Via Business Wire

12 Health Care Stocks Moving In Monday's Pre-Market Session ↗

May 16, 2022

Via Benzinga

Verastem Oncology Reports First Quarter 2022 Financial Results and Highlights Recent Company Progress

May 09, 2022

From Verastem Oncology

Via Business Wire

FDA Puts Blood Cancer Nods Under Scrutiny On Substantial Toxicity Profile Of PI3K Drugs ↗

April 21, 2022

The FDA aims to put the PI3K inhibitor drug class under a more stringent regulatory scope as the inhibitor has demonstrated substantial toxicity.

Via Benzinga

12 Health Care Stocks Moving In Thursday's Intraday Session ↗

April 14, 2022

Gainers

Via Benzinga

51 Biggest Movers From Thursday ↗

April 18, 2022

Gainers MedAvail Holdings, Inc. (NASDAQ: MDVL) shares surged 69.4% to close at $2.44 on Thursday. Ally Bridge Group recently reported a purchase of 21.176 million shares of...

Via Benzinga

Verastem Oncology Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

April 04, 2022

From Verastem Oncology

Via Business Wire

Benzinga's Top Ratings Upgrades, Downgrades For April 14, 2022 ↗

April 14, 2022

Upgrades

Via Benzinga

Verastem Oncology's Return On Capital Employed Insights ↗

March 29, 2022

According to data from Benzinga Pro, during Q4, Verastem Oncology's (NASDAQ:VSTM) reported sales totaled $545.00 thousand. Despite a 27.67% increase in earnings, the company posted a loss of $16.48...

Via Benzinga

Verastem Announces $150M Debt Financing To Support VS-6766, Defactinib Development ↗

March 28, 2022

Verastem Oncology Inc (NASDAQ: VSTM) entered into a credit facility with Oxford Finance LLC for

Via Benzinga

Verastem Oncology Reports Fourth Quarter and Full Year 2021 Financial Results and Highlights Recent Company Progress

March 28, 2022

From Verastem Oncology

Via Business Wire

Verastem Oncology Provides Financial Update to Support Development of VS-6766 and Defactinib in RAS Pathway-Driven Tumors

March 28, 2022

From Verastem Oncology

Via Business Wire

Verastem Oncology Names Preeminent Oncology Researcher Channing Der, PhD, to its Scientific Advisory Board

March 24, 2022

From Verastem Oncology

Via Business Wire

87 Biggest Movers From Yesterday ↗

March 10, 2022

Gainers Sunshine Biopharma, Inc. (NASDAQ: SBFM) shares jumped 150% to close at $3.80 on Wednesday. Sunshine Biopharma, last month, priced its 1.88 million unit uplisting to...

Via Benzinga

Truist Sees 350% Upside On This Cancer-Focused Biopharma Stock - Read Why ↗

March 09, 2022

Truist has initiated coverage on Verastem Oncology Inc (NASDAQ: VSTM) with a Buy rating and $6.00 price target, equivalent to approximately 350% upside. Analyst...

Via Benzinga

< Previous 1 2

...

5 6 7 8 9 10 11 12 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.